An ongoing phase 2 trial of up to 12 cycles of azacitidine + eprenetapropt post-alloHCT maintenance for patients with TP53-mutated AML/MDS demonstrated a 1-year RFS and OS of 58% and 79%, respectively, in the interim analysis of 33 patients (only 12% of whom had pre-alloHCT mutational clearance) [71]. This evidence concerns the gene TP53 and acute myeloid leukemia.